Business
Protagonist Therapeutics Announces Data from Phase 2 Rusfertide Study in Hereditary Hemochromatosis Selected for Oral Presentation at the Annual AASLD Meeting
NEWARK, Calif., Oct. 4, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that an abstract
About this update from Protagonist Therapeutics, Inc.
[{"type":"text","content":"NEWARK, Calif., Oct. 4, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) (\"Protagonist\" or \"the Company\") today announced that an abstract highlighting new results from its Phase 2 study of rusfertide in hereditary hemochromatosis (HH) has been selected for oral presentation at The Liver Meeting® 2021, hosted by the American Association for the Study of Liver Diseases (AASLD), taking place virtually November 12-15, 2021.\n\"We are pleased to have this opportunity to share new data on rusfertide that establishes clinical proof-of-concept in hereditary hemochromatosis,\" said Dinesh Patel, Ph.D., President and Chief Executive Officer of Protagonist. \"We are especially pleased and honored that this data has been selected by AASLD for an oral presentation. The Liver Meeting® brings together the world's most esteemed experts in hepatology.\" \nDetails for the AASLD 2021 oral presentation are as follows:\nTitle: \"An Open-Label Phase 2, Dose-Finding Study of the Safety and Efficacy of Rusfertide (PTG-300), a Hepcidin Mimetic, in Patients with Hereditary Hemochromatosis.\" Session Title: Parallel 3: Metabolic and Genetic Disease: Hemochromatosis, Wilsons Disease, Alpha-1 Antitrypsin Deficiency Presentation Type: Oral, Parallel Session Presentation Date and Time: Saturday, November 13, 2021, 10 a.m. PTAuthors: Kris V Kowdley, MD, FACP, FACG, AGAF, FAASLD, Dr. Nishit Modi, Dr. Frank Valone, Dr. Victor Priego, Dr. Frank Cole, Dr. Joe Pouzar and Dr. Suneel Gupta\nThe full abstract can be found in the October supplement of Hepatology, the peer-reviewed journal of AASLD, and on the AASLD website at https://www.aasld.org/the-liver-meeting/open-label-phase-2-dose-finding-study-safety-and-efficacy-rusfertide-ptg-300.\nAs previously announced on September 17, 2021, Protagonist's rusfertide clinical trials have been placed on clinical hold by the U.S. Food and Drug Administration (FDA). Protagonist is working closely with the FDA to determine next steps for the rusfertide development program. \nAbout Hereditary HemochromatosisHereditary hemochromatosis (HH) is a metabolic disorder caused by gene mutations that alter proteins responsible for regulating iron absorption, resulting in iron overload.1 The most common form of HH, hemochromatosis type 1, is characterized by defects in the HFE gene that lead to deficient levels of ...